New Horizons in the Treatment of Osteosarcoma
Paul S. Meltzer, Lee J. Helman
Abstract
Osteosarcoma, which is most common in people 10 to 30 years of age, is generally treated with resection and adjuvant chemotherapy. Detection of gene rearrangements, copy-number variations, and targeted disruption of tumor suppressors by whole-genome sequencing has not yet led to improved treatment.
Topics & Concepts
New horizonsOsteosarcomaMedicineAdjuvantCancer researchTumor suppressor geneCancerResectionGeneInternal medicineSuppressorOncologySarcoma Diagnosis and TreatmentCancer Genomics and DiagnosticsMolecular Biology Techniques and Applications